PMID- 29980853
OWN - NLM
STAT- MEDLINE
DCOM- 20181126
LR  - 20181126
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Linking)
VI  - 265
IP  - 9
DP  - 2018 Sep
TI  - Dysfunctional inhibitory control in Parkinson's disease patients with
      levodopa-induced dyskinesias.
PG  - 2088-2096
LID - 10.1007/s00415-018-8945-1 [doi]
AB  - INTRODUCTION: Chronic dopamine replacement therapies in Parkinson's disease can
      induce side effects, such as levodopa-induced dyskinesias and impulse control
      disorders. A dysfunction of inhibitory brain networks has been related to both
      disorders; however, there is no clear behavioral evidence supporting this
      hypothesis. We aimed to determine whether PD patients with levodopa-induced
      dyskinesias show features of increased impulsivity in parallel with altered motor
      inhibition. METHODS: Two matched samples of Parkinson's disease patients with (n 
      = 14) or without (n = 14) levodopa-induced dyskinesias and a control group (n =
      10) participated in the study. All groups were evaluated by the Barratt
      Impulsiveness Scale-11 to assess impulsivity traits. Furthermore, participants
      performed a stop signal task to evaluate reactive-motor inhibition and a Go/NoGo 
      task to evaluate proactive-inhibitory control. PD patients were tested both in
      OFF and ON levodopa medication. RESULTS: Parkinson's disease patients with
      levodopa-induced dyskinesias showed higher impulsivity scores than PD patients
      without levodopa-induced dyskinesias. Dyskinetic patients presented also delayed 
      stop signal reaction times indicating a worse performance in reactive inhibition.
      The slowness in inhibiting a motor command correlated with the impulsiveness
      scores. Furthermore, in the dyskinetic group, a positive correlation was found
      between stop reaction times and the severity of involuntary movements. Under the 
      effect of levodopa, all patients were faster but dyskinetic patients were
      significantly less accurate in proactive inhibition. CONCLUSION: Inhibitory
      control is compromised in dyskinetic patients in parallel with increased
      impulsivity, revealing an impairment of motor and behavioral inhibitory control
      in Parkinson's disease patients with levodopa-induced dyskinesias.
FAU - Picazio, Silvia
AU  - Picazio S
AD  - Non-Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Via Ardeatina,
      306, 00179, Rome, Italy.
FAU - Ponzo, Viviana
AU  - Ponzo V
AD  - Non-Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Via Ardeatina,
      306, 00179, Rome, Italy.
FAU - Caltagirone, Carlo
AU  - Caltagirone C
AD  - Non-Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Via Ardeatina,
      306, 00179, Rome, Italy.
AD  - Department of System Medicine, University of Rome Tor Vergata, Via Montpellier,
      1, 00133, Rome, Italy.
FAU - Brusa, Livia
AU  - Brusa L
AD  - UOC Neurologia, Ospedale S. Eugenio, Piazzale dell'Umanesimo, 10, 00144, Rome,
      Italy.
FAU - Koch, Giacomo
AU  - Koch G
AD  - Non-Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Via Ardeatina,
      306, 00179, Rome, Italy. g.koch@hsantalucia.it.
AD  - Stroke Unit, Department of Neuroscience, Policlinic Tor Vergata, Via Montpellier,
      1, 00133, Rome, Italy. g.koch@hsantalucia.it.
LA  - eng
PT  - Journal Article
DEP - 20180706
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Antiparkinson Agents)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Aged
MH  - Antiparkinson Agents/adverse effects/therapeutic use
MH  - Dyskinesia, Drug-Induced/*physiopathology/psychology
MH  - Female
MH  - Humans
MH  - *Impulsive Behavior/drug effects
MH  - Levodopa/adverse effects/therapeutic use
MH  - Male
MH  - *Motor Activity/drug effects
MH  - Parkinson Disease/drug therapy/*physiopathology/psychology
MH  - Reaction Time/drug effects
OTO - NOTNLM
OT  - Go/NoGo
OT  - Impulsivity
OT  - Levodopa-induced dyskinesia
OT  - Motor inhibition
OT  - Parkinson's disease
OT  - Stop-signal task
EDAT- 2018/07/08 06:00
MHDA- 2018/11/27 06:00
CRDT- 2018/07/08 06:00
PHST- 2018/02/01 00:00 [received]
PHST- 2018/06/18 00:00 [accepted]
PHST- 2018/05/28 00:00 [revised]
PHST- 2018/07/08 06:00 [pubmed]
PHST- 2018/11/27 06:00 [medline]
PHST- 2018/07/08 06:00 [entrez]
AID - 10.1007/s00415-018-8945-1 [doi]
AID - 10.1007/s00415-018-8945-1 [pii]
PST - ppublish
SO  - J Neurol. 2018 Sep;265(9):2088-2096. doi: 10.1007/s00415-018-8945-1. Epub 2018
      Jul 6.